AAAAAA

   
Results: 1-7 |
Results: 7

Authors: Rueffer, U Breuer, K Josting, A Lathan, B Sieber, M Manzke, O Grotenhermen, FJ Tesch, H Bredenfeld, H Koch, P Nisters-Backes, H Wolf, J Engert, A Diehl, V
Citation: U. Rueffer et al., Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment, ANN ONCOL, 12(9), 2001, pp. 1307-1311

Authors: Pfreundschuh, M Hasenclever, D Loeffler, M Ehninger, G Schmitz, N Kirchner, H Koch, P Lathan, B Rueffer, U Sextro, M Franklin, J Tesch, H Diehl, V
Citation: M. Pfreundschuh et al., Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF, ANN ONCOL, 12(4), 2001, pp. 471-477

Authors: Duhmke, E Franklin, J Pfreundschuh, M Sehlen, S Willich, N Ruhl, U Muller, RP Lukas, P Atzinger, A Paulus, U Lathan, B Ruffer, U Sieber, M Wolf, J Engert, A Georgii, A Staar, S Herrmann, R Beykirch, M Kirchner, H Emminger, A Greil, R Fritsch, E Koch, P Drochtert, A Brosteanu, O Hasenclever, D Loeffler, M Diehl, V
Citation: E. Duhmke et al., Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone, J CL ONCOL, 19(11), 2001, pp. 2905-2914

Authors: Staib, P Schinkothe, T Wiedenmann, S Dimski, T Schoch, C Voliotis, D Horn, PA Tesch, H Lathan, B Diehl, V
Citation: P. Staib et al., Prognostic relevance of in-vitro drug sensitivity testing in adult AML, HEMAT BLOOD, 40, 2001, pp. 251-256

Authors: Diehl, V Franklin, J Hasenclever, D Tesch, H Pfreundschuh, M Lathan, B Paulus, U Sieber, M Ruffer, JU Sextro, M Engert, A Wolf, J Hermann, R Holmer, L Stappert-Jahn, U Winnerlein-Trump, E Wulf, G Krause, S Glunz, A von Kalle, K Bischoff, H Haedicke, C Duhmke, E Georgii, A Loeffler, M
Citation: V. Diehl et al., BEACOPP: A new regimen for advanced Hodgkin's disease, ANN ONCOL, 9, 1998, pp. 67-71

Authors: Diehl, V Franklin, J Hasenclever, D Tesch, H Pfreundschuh, M Lathan, B Paulus, U Sieber, M Rueffer, JU Sextro, M Engert, A Wolf, J Hermann, R Holmer, L Stappert-Jahn, U Winnerlein-Trump, E Wulf, G Krause, S Glunz, A von Kalle, K Bischoff, H Haedicke, C Duehmke, E Georgii, A Loeffler, M
Citation: V. Diehl et al., BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group, J CL ONCOL, 16(12), 1998, pp. 3810-3821

Authors: Tesch, H Diehl, V Lathan, B Hasenclever, D Sieber, M Ruffer, U Engert, A Franklin, J Pfreundschuh, M Schalk, KP Schwieder, G Wulf, G Dolken, G Worst, P Koch, P Schmitz, N Bruntsch, U Tirier, C Muller, U Loeffler, M
Citation: H. Tesch et al., Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's Lymphoma Study Group, BLOOD, 92(12), 1998, pp. 4560-4567
Risultati: 1-7 |